Back to top
more

CelSci (CVM)

(Delayed Data from AMEX)

$6.61 USD

6.61
1,044,654

+0.51 (8.36%)

Updated Jan 14, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.25%
2Buy18.80%
3Hold10.34%
4Sell6.03%
5Strong Sell2.82%
S&P50011.35%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (156 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

0 items in cart

CelSci Corporation [CVM]

Reports for Purchase

Showing records 1 - 20 ( 29 total )

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 1

08/17/2020

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 2

08/16/2020

Company Report

Pages: 4

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 3

06/29/2020

Company Report

Pages: 4

Fireside Chat Shows LEAPS Could Be a Potential Leap Ahead

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 4

02/14/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 5

01/13/2020

Company Report

Pages: 20

We are initiating coverage with a Buy rating and $18 price target.

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 50.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 6

12/20/2019

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 7

10/15/2019

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 8

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CVM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 9

08/19/2019

Company Report

Pages: 6

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 10

05/20/2019

Company Report

Pages: 6

Price: 24.95

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 11

05/02/2019

Company Report

Pages: 6

Multikine Phase 3 nearing 3-Year Milestone

Provider: Dawson James Securities, Inc.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 12

02/25/2019

Company Report

Pages: 5

Price: 24.95

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 13

01/31/2019

Company Report

Pages: 28

Price: 24.95

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 14

08/01/2018

Company Report

Pages: 5

Multikine Read-Out Could Come in 2019

Provider: Dawson James Securities, Inc.

Analyst: WASSERMAN R

Price: 10.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 15

10/12/2017

Company Report

Pages: 5

Neutral - Multikine Back on Track

Provider: Dawson James Securities, Inc.

Analyst: WASSERMAN R

Price: 10.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 16

12/12/2016

Daily Note

Pages: 3

Termination of Coverage -Analyst(s) Departure

Provider: Dawson James Securities, Inc.

Price: 10.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 17

09/27/2016

Company Report

Pages: 4

FDA Puts Phase III Multikine® Trial on Clinical Hold

Provider: Dawson James Securities, Inc.

Analyst: GRISEWOOD S

Price: 10.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 18

08/31/2016

Daily Note

Pages: 3

Suspended research coverage due to the termination or loss of the primary and/or secondary analysts responsible for coverage.

Provider: Dawson James Securities, Inc.

Price: 10.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 19

12/16/2015

Company Report

Pages: 6

Could 2016 be the year for Multikine?

Provider: Dawson James Securities, Inc.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: CelSci Corporation

Industry: Medical - Biomedical and Genetics

Record: 20

06/29/2015

Company Report

Pages: 4

Suspending Coverage of CELSCI Corporation

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 10.00

Research Provided by a Third Party